HC Wainwright Has Pessimistic View of MediWound Q2 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings estimates for MediWound in a research report issued to clients and investors on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings of ($0.91) per share for the quarter, down from their previous estimate of ($0.68). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for MediWound’s Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($2.01) EPS, FY2027 earnings at ($2.09) EPS, FY2028 earnings at ($0.93) EPS and FY2029 earnings at $1.04 EPS.

MDWD has been the topic of several other reports. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday. Oppenheimer reiterated an “outperform” rating and issued a $32.00 price target (down from $33.00) on shares of MediWound in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $34.00.

MediWound Stock Performance

Shares of MediWound stock opened at $14.33 on Monday. The company’s 50-day moving average price is $16.62 and its two-hundred day moving average price is $17.43. MediWound has a 52 week low of $14.14 and a 52 week high of $22.50. The stock has a market cap of $184.14 million, a PE ratio of -6.34 and a beta of 0.16.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.42. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $3.37 million. During the same period in the previous year, the business earned ($0.07) earnings per share.

Institutional Trading of MediWound

Several institutional investors and hedge funds have recently bought and sold shares of MDWD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the period. Rhumbline Advisers raised its holdings in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 481 shares during the period. Russell Investments Group Ltd. raised its holdings in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. Marshall Wace LLP acquired a new stake in MediWound during the 2nd quarter worth about $317,000. Finally, The Manufacturers Life Insurance Company raised its holdings in MediWound by 104.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 13,312 shares during the period. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.